Arcutis Biotherapeutics (ARQT) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ARQT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Aberdeen Group plc grew its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) by 9.7% in a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,2…

New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their families Findings further support investigati…

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) EVP Masaru Matsuda sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $34…

WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, t…

New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZORYVE cream treatment …

Arcutis Biotherapeutics, Inc. ( ARQT ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Brian Schoelkopf - Head of Investor Relations Todd Watanabe - President, CEO & Director Robert Lisicki - Inte…

Arcutis Biotherapeutics NASDAQ: ARQT raised its full-year 2026 net revenue guidance after third-quarter sales of its ZORYVE skin treatments rose 45% from a year earlier, driven primarily by increased patient demand.…

Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.06 per share a year ago.…

Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth Raised 2026 full-year net product …

Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer.…

WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, t…

Arcutis today announced that it will report its Q3 2026 financial results and provide a business update after the U.S. financial markets close on Nov 4.…

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) Director Howard Welgus sold 4,728 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $…

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) stock traded higher Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $48 price forecast, citing strong Zoryve sales growth and expansion oppo…

Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to…

Newly created award category highlights innovation in prescription skin treatment ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to …

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) have earned an average rating of "Moderate Buy" from the nine brokerages that are currently covering the stock, MarketBeat reports. Three research …

WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, t…

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) insider Masaru Matsuda sold 3,674 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an averag…

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.…

Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, …

WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, …
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 24. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

